Cost-Effectiveness of Histamine2Receptor Antagonists Versus Proton Pump Inhibitors for Stress Ulcer Prophylaxis in Critically Ill Patients.
To determine the cost-effectiveness of stress ulcer prophylaxis with histamine2receptor antagonists (H2RAs) versus proton pump inhibitors (PPIs) in critically ill and mechanically ventilated adults.



A decision analytic model estimating the costs and effectiveness of stress ulcer prophylaxis (with H2RAs and PPIs) from a health care institutional perspective.



Adult mixed intensive care unit (ICU) population who received an H2RA or PPI for up to 9 days.



Effectiveness measures were mortality during the ICU stay and complication rate. Costs (2015 U.S. dollars) were combined to include medication regimens and untoward events associated with stress ulcer prophylaxis (pneumonia, Clostridium difficile infection, and stress-related mucosal bleeding). Costs and probabilities for complications and mortality from complications came from randomized controlled trials and observational studies. A base case scenario was developed with pooled data from an observational study and meta-analysis of randomized controlled trials. Scenarios based on observational and meta-analysis data alone were evaluated. Outcomes were expected and incremental costs, mortalities, and complication rates. Univariate sensitivity analyses were conducted to determine the influence of inputs on cost, mortality, and complication rates. Monte Carlo simulations evaluated second-order uncertainty. In the base case scenario, the costs, complication rates, and mortality rates were $9039, 17.6%, and 2.50%, respectively, for H2RAs and $11,249, 22.0%, and 3.34%, respectively, for PPIs, indicating that H2RAs dominated PPIs. The observational study-based model provided similar results; however, in the meta-analysis-based model, H2RAs had a cost of $8364 and mortality rate of 3.2% compared with $7676 and 2.0%, respectively, for PPIs. At a willingness-to-pay threshold of $100,000/death averted, H2RA therapy was superior or preferred 70.3% in the base case and 97.0% in the observational study-based scenario. PPI therapy was preferred 87.2% in the meta-analysis-based scenario.



Providing stress ulcer prophylaxis with H2RA therapy may reduce costs, increase survival, and avoid complications compared with PPI therapy. This finding is highly sensitive to the pneumonia and stress-related mucosal bleeding rates and whether observational data are used to inform the model.
Department of Pharmacy Practice, University of Arkansas for Medical Sciences, College of Pharmacy, Little Rock, Arkansas.
Drayton A
DA
Hammond
Division of Pharmaceutical Evaluation and Policy, University of Arkansas for Medical Sciences, College of Pharmacy, Little Rock, Arkansas.
Niranjan
N
Kathe
Division of Pharmaceutical Evaluation and Policy, University of Arkansas for Medical Sciences, College of Pharmacy, Little Rock, Arkansas.
Anuj
A
Shah
Department of Pharmacy Practice, University of Arkansas for Medical Sciences, College of Pharmacy, Little Rock, Arkansas.|Division of Pharmaceutical Evaluation and Policy, University of Arkansas for Medical Sciences, College of Pharmacy, Little Rock, Arkansas.
Bradley C
BC
Martin
D003362:Cost-Benefit Analysis; D016638:Critical Illness; D003661:Decision Support Techniques; D017048:Health Care Costs; D006635:Histamine H2 Antagonists / Q000191:economics / Q000627:therapeutic use*; D006801:Humans; D009010:Monte Carlo Method; D010437:Peptic Ulcer / Q000517:prevention & control*; D054328:Proton Pump Inhibitors / Q000191:economics / Q000627:therapeutic use*; D013315:Stress, Psychological / Q000150:complications*
D006635:Histamine H2 Antagonists; D054328:Proton Pump Inhibitors
Cost-effectiveness; critically ill; decision model; histamine2 receptor antagonist; proton pump inhibitor; stress ulcer prophylaxis